Yale SOM’s Michael Sinkinson found that fewer people get life-savings statins during primary season, when pharmaceutical ads are displaced by political ads.

After patients are treated at in-network hospitals, they often receive large, unexpected bills from out-of-network doctors. A new study finds that out-of-network charges from anesthesiologists, pathologists, radiologists, and assistant surgeons increase spending by $40 billion annually. 

Research co-authored by Yale SOM’s Amandine Ody-Brasier suggests that ratings based on self-reporting may be unreliable, and offers a solution: hide the thresholds for jumping to higher ratings.

A new study led by Yale SOM’s Arthur J. Swersey, using decision analysis techniques, finds that increasing the number of biopsy needles and using probability modeling to analyze the results can help prevent unnecessary treatment while identifying dangerous cancers.

This month, the Trump administration announced a series of steps to overhaul the kidney transplant system. We asked operations expert Vahideh Manshadi if the changes could make a difference for patients.  

Yale SOM’s Vahideh Manshadi and her co-authors examined the methodology of kidney exchange registries, and found that registries can find more matches if they collaborate to build a unified database.

A recent lawsuit alleged that a billionaire investor bought the rights to a new drug just to eliminate a potential competitor. We asked Yale SOM's Florian Ederer to explain why a "catch-and-kill" merger can be damaging and what to do about the phenomenon.

Dr. Greg Licholai writes that the complexity of the healthcare system has generated unexpected incentives—one of which is that we have come to rely on the industry for jobs.  

Prof. Scott Morton called a private healthcare system without competitive pressure “the worst of both worlds” in terms of costs.